Ingo Chakravarty

Ingo Chakravarty is an Operating Partner at Northpond Ventures. He is a board director at Camp4 Therapeutics, Encodia, Inflammatix, Scipher Medicine, Selux Diagnostics, Sherlock Biosciences, and SpeeDx. Ingo has 30 years of experience in building, scaling and leading high-performance teams and companies in the diagnostics and precision medicine sectors. He was recently President and CEO of Mesa, which he successfully sold to Thermo Fisher Scientific in 2021. Prior to Mesa, Ingo held multiple executive roles in the diagnostics and precision medicine sectors, including CEO of Navican Genomics, SVP and GM of GenMark Diagnostics, (acquired by Roche), VP and GM of Gen-Probe (acquired by Hologic), and various leadership roles at Ventana Medical Systems (acquired by Roche). He received a degree in electrical engineering from the Friedrich Haecker School in Germany.